Lewes, DE -- (SBWIRE) -- 04/28/2015 -- PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015 report analyses that PD-1 and PD-L1 inhibitors are among the highly targeted mechanisms in oncology. There are 34 drugs are in pipeline. Out of 34 drugs, 22 are in combinations with other therapeutics agents. Focus of development is mainly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) and Programmed death-ligand 1 (PD-L1). Continuation of expansion of the combination regimens is likely to be one of the main themes surrounding immunotherapies as these partnerships are the key to developing competitively strong therapy regimens.

According to Publisher, the future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. The market for PD-1 and PD-L1 drugs might be billions of dollars richer than many believe. These drugs which include Bristol-Myers' Opdivo and Merck's Keytruda, are going to be Blockbuster in upcoming years.

Scope

- Overview of PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA) and biomarkers of PD-1 and PD-L1 inhibitors

- The report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry and impact on market after expiry and detail profiling of Pipeline assets

- It also includes Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented in to major geographies

- Key topics covered include strategic competitor assessment, market characterization, opportunities, barriers and challenges in the market along with SWOT analysis of the PD-1 and PD-L1 inhibitors market

- Pipeline analysis: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates

- Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of market with upcoming blockbuster molecules and their impact on overall market.

Reasons to Buy

- The report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for PD-1 and PD-L1 inhibitors.

- Develop business strategies by understanding the trends shaping and driving for Immunotherapeutics market

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding PD-a and PD-L1 inhibitors pipeline in-depth

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners to enhance and expand business potential and scope

- Identifying the upcoming leaders in the PD-1 and PD-L1 inhibitors market in the coming years.

Spanning over 85 pages, "PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015" report covers the Introduction, Executive Summary, Epidemiology, Market Overview, Combination therapy, Drug Candidate Profiles, SWOT Analysis, Market Research Methodology.

For further information on this report, please visit- http://www.marketresearchreports.com/delveinsight/pd-1-and-pd-l1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2015

Find all Pharmacy Reports at: http://www.marketresearchreports.com/pharmacy

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter